Stock Ratings / Health Care / ZURA / insiders

TRXB (49) KYTX (42) FENC (36) AGMB (51) ⌘ Pro Terminal →

Zura Bio Limited (Class A) (ZURA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.85 -11.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.76

Zura Bio Limited (Class A) (ZURA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $370.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.76 (-2.26%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-13% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZURA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY ZURA SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (28% of score)

FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 48.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.00-3% Next Q

Q2 (-2Q)

Grade E$3.88-13.4% Next Q

Q3 (-1Q)

Grade E$3.36+14.6% Next Q

Current

Grade E$3.85-9.8% Hist 90D α

Trajectory: E (37) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZURA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZURA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.66) and Max Pain ($4.04) forces dealer call-delta covering toward $7.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZURA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZURA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ZURA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ZURA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ZURA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZURA)

✓Walkthrough of ZURA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZURA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -24.21%📐 HORIZONTAL RANGE

2026-10-30O $3.81H $4.06L $3.65C $3.85VOL 4.07M

RES: $8.03SUP: $3.16SMA50: $4.66SMA200: $5.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZURA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZURA Butterfly Map → + Track ZURA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZURA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZURA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZURA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZURA)

Health Care Rank #953 of 1016 ⚔️ TRXB vs ZURA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZURA vs. TRXB, KYTX, FENC, AGMB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zura Bio Limited (Class A) (ZURA) ranks #953 by composite RQD confidence (29/100, grade E) and #491 by equity capitalization ($370.9M). Within this direct 5-issuer industry benchmark cohort, ZURA leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. AGMB currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with ZURA at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZURA ACTIVE Zura Bio Limited (Class A)	E	29/100	—	—	-35.0%	-11.49%	$370.9M	Benchmark Subject
TRXB TRex Bio Inc.	D	49/100	—	—	—	-6.31%	$371.1M	/trxb-vs-zura →
KYTX Kyverna Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.68%	$361.8M	/kytx-vs-zura →
FENC Fennec Pharmaceuticals Inc.	D-	36/100	—	—	-25.9%	+0.74%	$383.6M	/fenc-vs-zura →
AGMB AgomAb Therapeutics NV	D	51/100	—	—	—	-0.13%	$391.5M	/agmb-vs-zura →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001855644

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zura Bio Limited (Class A) (ZURA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$68.7M, operating cash flow of -$64.8M, and free cash flow of -$64.9M (-130.6% YoY). On the balance sheet, ZURA closed FY2025 with $113.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$68.7M	-$64.8M	-$64.9M	$113.9M	—
FY2024 (FY)	2024-12-31	$0	-$52.4M	-$28.1M	-$28.2M	$179.5M	—
FY2023 (FY)	2023-12-31	$0	-$60.4M	-$15.1M	-$15.1M	—	—

3. ZURA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Zura Bio Limited (Class A) (NASDAQ: ZURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.85 (-11.49% 1D, market cap $370.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZURA ranks #953 in composite RQD confidence.

How does ZURA compare to TRXB and KYTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ZURA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TRXB (TRex Bio Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $371.1M) and KYTX (Kyverna Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $361.8M). Among the 5-stock peer group, ZURA leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZURA?

Per ZURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855644), Zura Bio Limited (Class A) generated $0 in revenue, -$68.7M in net income, and -$64.9M in free cash flow against $113.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZURA trading relative to its 50-day, 200-day, and 52-week technical levels?

ZURA last traded at $3.85 (-11.49% on volume of 3,354,973 shares), positioning the stock -17.38% below its 50-day simple moving average ($4.66) and -26.53% below its 200-day simple moving average ($5.24). Across its 52-week range of $3.25 to $7.44, ZURA sits at the 14.3% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.37 to $4.33).

ZURA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ZURA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ZURA leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: ZURA RQD Cockpit ZURA 12M Forecast ZURA Earnings & Move ZURA Dividends & DRIP ZURA Insiders & 13F ZURA Whale Options ZURA Profit Sankey ZURA News & Why